Skip to main content
Premium Trial:

Request an Annual Quote

Immune Tolerance Network Chooses Expression Analysis as Microarray Core Facility

NEW YORK, Jan. 25 (GenomeWeb News) - The Immune Tolerance Network has chosen Expression Analysis to serve as its microarray core facility, the company said today.

 

Using Affymetrix GeneChips, EA over the next 20 months will help support clinical trials for the ITN, an international collaborative research project involving more than 70 scientists and clinical professionals.

Terms of the deal call for EA to provide the ITN with a single-source environment for processing clinical trials samples submitted from multiple locations. EA said it expects to process several thousand clinical samples during the initial contract period.

Founded in Durham, NC, in 2001, EA offers high-throughput sample processing and statistical support for microarray-based gene-expression, genotyping, and resequencing.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.